

TABLE OF CONTENTS

Section	Description	Page No.
Contents		I to VI
List of Tables		VII to IX
List of Figures		X to XIV
List of Abbreviations		XV to XIX
Abstract		XX
Chapter 1: Introduction		
1.1	Chemotherapy-induced nausea and vomiting (CINV)	1
	1.1.1 Background	1
	1.1.2 Current Treatments	2
	1.1.3 Choice of drugs	3
1.2	Hypothesis	5
1.3	Research Statement	6
	1.3.1 Benefits of combination of drugs for effective treatment	6
	1.3.2 Long-acting Formulations (LAFs)	7
1.4	In-silico modelling:	8
	1.4.1 Introduction	8
	1.4.2 Allometry	9
	1.4.3 Wajima-Dedrick plots	10
	1.4.4 PBPK and PBBM	10
1.5	Aim	11
1.6	Objectives	11
1.7	Plan of work	11
1.8	References	12
Chapter 2: Literature Review		
2.1	Introduction	23
2.2	Pathophysiology of CINV	23
2.3	Current Treatments of CINV	24
2.4	Drug Profiles	25
2.5	Sustained Release Injectable Formulations	32

Section		Description	Page No.
	2.5.1	Introduction	32
	2.5.2	Janus Particles	33
2.6	Manufacturing methods of Janus particles		37
	2.6.1	Emulsion-Solvent Evaporation method	37
	2.6.2	Other methods	38
2.7	<i>In-vitro</i> drug release testing methods		39
2.8	Accelerated vs Real time drug release method		40
2.9	Design of experiments		41
2.10	In-silico modelling		43
	2.10.1	Allometry	43
	2.10.2	Wajima-Dedrick plots	51
	2.10.3	Dissolution, PBPK and PBBM modelling	52
2.11	References		54
Chapter 3: In-silico Model development			
3.1	Development of model from animal data		69
	3.1.1	Collection of data from literature	69
	3.1.2	Allometric methods	69
	3.1.3	Prediction of Human clearance	69
	3.1.4	Prediction of Human volume of distribution	71
	3.1.5	Human <i>in-vivo</i> plasma profile prediction	72
	3.1.6	Wajima (Css-MRT) Approach	72
	3.1.7	Dedrick plot	73
3.2	Development and verification of pharmacokinetic models in human		75
	3.2.1	PBPK model of Amisulpride	75
	3.2.2	PBPK model of Granisetron	78
3.3	Parameter sensitivity analysis (PSA)		82
3.4	Model validation		87
3.5	Identification of target plasma concentration levels for sustained release formulations		93
3.6	Development of dissolution model for target dissolution profile		96

Section	Description	Page No.	
3.7	Selection of desired dose	97	
3.8	References	98	
Chapter 4: Pre-formulation studies			
4.1	Introduction	102	
4.2	Materials	102	
4.3	Instruments	102	
4.4	Authentication of drugs and pre-formulation studies	102	
	4.4.1	Organoleptic properties	102
	4.4.2	Determination of Melting point	103
	4.4.3	Solubility Data	103
	4.4.4	UV Absorption Spectrum	103
	4.4.5	FTIR analysis	105
	4.4.6	Thermal analysis using DSC	108
4.5	References	110	
Chapter 5: Analytical methods			
5.1	Introduction	112	
5.2	Materials	112	
5.3	Instruments	112	
5.4	Reagents and Solutions preparations	113	
	5.4.1	Preparation of 0.1N HCl	113
	5.4.2	Buffer solution for HPLC	113
	5.4.3	Mobile phase for HPLC	113
	5.4.4	Diluent for HPLC	113
5.5	Validation of analytical methods	113	
	5.5.1	Linearity and range	113
	5.5.2	Robustness	114
	5.5.3	Method sensitivity	114
	5.5.4	Precision	114
	5.5.5	Accuracy	114
	5.5.6	Specificity	114
5.6	Estimation of Amisulpride by UV Visible spectrophotometer	114	

Section	Description	Page No.
	5.6.1 Amisulpride stock solutions preparation	115
	5.6.2 Standard Amisulpride Solutions Preparation	115
	5.6.3 Analytical Wavelength Determination	115
	5.6.4 Calibration Curve preparation	115
5.7	Estimation of Granisetron by UV Visible spectrophotometer	115
	5.7.1 Granisetron stock solutions preparation	115
	5.7.2 Standard Granisetron Solutions Preparation	115
	5.7.3 Analytical Wavelength Determination	115
	5.7.4 Calibration Curve preparation	115
5.8	Test sample preparation for UV	116
5.9	Simultaneous estimation by UV Visible spectrophotometer	116
5.10	Simultaneous estimation of Amisulpride and granisetron by HPLC	116
	5.10.1 Standard preparation	116
	5.10.2 Test sample preparation for HPLC	117
	5.10.3 Instrumental conditions	117
	5.10.4 Calculations	118
	5.10.5 Calibration Curve preparation	118
5.11	Results & Discussion	119
	5.11.1 UV Spectrophotometric methods	119
	5.11.2 HPLC Method	126
5.12	Conclusion	130
5.13	References	131
Chapter 6: Formulation development		
6.1	Introduction	132
6.2	Selection of Polymers	132
6.3	Selection of method	132
6.4	Defining the Critical Quality Attributes	133
6.5	Identification and Evaluation of Material attributes and Process Parameters	134
6.6	Risk assessment	136

Section		Description	Page No.
6.7	Materials		138
6.8	Equipment's		138
6.9	Formulation development		138
	6.9.1	Preparation of microspheres for Amisulpride	138
	6.9.2	Preparation of microspheres for Granisetron	139
	6.9.3	Preparation of Janus microspheres for Amisulpride and Granisetron	139
	6.9.4	Preparation of diluent	139
6.10	Design of experiments		140
	6.10.1	Screening design	140
	6.10.2	Effect on particle Size in screening design	143
	6.10.3	Effect on entrapment efficiency in screening design	147
	6.10.4	Effect on Drug Loading in screening design	153
	6.10.5	Response surface design	160
	6.10.6	Effect on particle Size in confirmatory trials	163
	6.10.7	Effect on entrapment efficiency in confirmatory trials	166
	6.10.8	Effect on Drug Loading in confirmatory trials	171
	6.10.9	Effect on Drug Release in confirmatory trials	176
6.11	Updated risk assessment		181
6.12	Design space		182
6.13	References		183
Chapter 7: Formulation evaluation			
7.1	Introduction		185
7.2	<i>In-vitro</i> characterization studies		186
	7.2.1	Determination of Yield	186
	7.2.2	FTIR analysis	186
	7.2.3	Thermal analysis by DSC	186
	7.2.4	Particle size analysis	187
	7.2.5	Morphology by optical microscopy	188
	7.2.6	Morphology by Scanning electron microscopy	190
	7.2.7	Drug loading and Entrapment efficiency (%)	191

Section		Description	Page No.
	7.2.8	Micromeritics	191
	7.2.9	<i>In-vitro</i> Drug release studies	192
	7.2.10	<i>In-vitro</i> Drug release kinetics	197
	7.2.11	Results and Discussion of IVRT data	200
	7.2.12	Stability of Formulations	200
	7.2.13	Bio-interactions of prepared formulations	201
7.3	In-silico evaluation		202
	7.3.1	Prediction of <i>In-vivo</i> pharmacokinetics	202
	7.3.2	Virtual bioequivalence studies	203
	7.3.3	Predictive IVIVC to establish design space	204
7.4	References		208
Chapter 8: Summary and conclusion			
8.1	Summary		211
8.2	Conclusion		215
Annexure			
I	Publications and Presentations		